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This study explored patients’ perspectives about taking the new direct-acting
antivirals (DAAs) for the treatment of Hepatitis C (i.e., sofosbuvir, simeprevir,
ledipasvir/sofosbuvir, ombitasvir/paritraprevir/ritonavir and dasabuvir) to
identify facilitators of medication adherence. The project was conducted using
semi-structured interviews with 12 Veterans who successfully completed a
treatment course on the new DAAs. The Veterans were recruited using
purposive sampling. The data collected from the semi-structured interviews was
analyzed using an adapted open coding method outlined by Auerbach and
Silverstein (2003), with identification of relevant text sub-grouped into
repeating ideas, and then creation of overarching themes and constructs.
Results obtained provide insight into factors that influenced the Veterans’
medication adherence during the course of treatment. Key constructs,
embodying major themes supported by repeating ideas, included recognizing
the “burden of HCV,” the importance of the “treatment engagement process,”
and anticipation of “positive outcomes.” Clinical implications are discussed.
Keywords: Hepatitis C, Adherence, Health Care, Health Behavior, Progressive,
Quality of Life, Qualitative Research, Semi-Structured Interviews
Hepatitis C virus (HCV) is a widely recognized public health concern in the United
States (Centers for Disease Control and Prevention [CDC], 1998; Edlin et al., 2001; Evon et
al., 2013; Lawitz et al., 2013; Ly et al., 2012; Moyer, 2013; Sloan, Straits-Troster, Dominitz,
& Kivlahan, 2004; Veterans Health Administration, 2015). It is the most common chronic
blood borne infection in this country (Alter, 1999; CDC, 2011), particularly in the Veteran
population. Globally, about 185 million individuals are infected with HCV, which is a
seroprevalence rate of HCV of 2.8% (Hanafiah, Groeger, Flaxman, & Wiersma, 2013). While
in the general US population, prevalence of HCV is estimated at 1.8% (CDC, 1998), the
prevalence among Veterans enrolled in the Veterans Healthcare Administration (VHA) is much
higher, ranging between 8% - 10% (CDC, 1998; Lawitz et al., 2013; Ly et al., 2012; Sloan et
al., 2004; Slomski, 2014). VHA is the largest HCV care provider in the United States, serving
between 174,000 and 180,000 Veterans between 2009 and 2013 (Veterans Health
Administration, 2015). The consequences of chronic HCV infection are well known and
mainly consist of cirrhosis and hepatocellular carcinoma that lead to increased healthcare costs
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and an increased mortality. Projected medical costs for treating HCV between 2010 and 2019
could reach $10.7 billion in direct care and a $54.2 billion societally (Wong, McQuillan,
McHutchison, & Poynard, 2000). HCV has now surpassed human immunodeficiency virus as
a leading cause of death in the United States (Rustgi, 2007).
New Direct-Acting Antivirals for HCV
New US Food and Drug Administration (FDA) approved direct-acting antivirals
(DAAs) (specifically, sofosbuvir, simeprevir, the combination ledipasvir/sofosbuvir, and the
combination ombitasvir/paritraprevir/ritonavir and dasabuvir) became available to patients in
2014 at a cost between $66,000 and $84,000 per person for a 12-week course (Brennan &
Shrank, 2014; Lawitz et al., 2013; Reau & Jensen, 2014; Slomski, 2014; Steinbrook &
Redberg, 2014; Veterans Health Administration, 2015). Some patients who have cirrhosis need
a 24-week course of these medications (American Association for the Study of Liver Diseases
and the Infectious Diseases Society of America, 2015; Veterans Health Administration, 2015).
Compared to traditional interferon-based treatment regimens for Hepatitis C (HCV), these new
medications have many benefits. One such benefit is that the new medications to treat HCV
have a much lower side effect profile (e.g., less nausea/vomiting, dizziness, depression, sleep
problems, skin reactions, headaches, fatigue, flu-like symptoms). Another advantage to taking
the new medications is the reduced treatment length and better cure rates (8-24 weeks with a
cure rate of 80% to over 90% instead of about 48 weeks with a 45-75% cure rate with
interferon-based regimens, depending on a person’s genotype [Brennan & Shrank, 2014;
Lawitz et al., 2013; Reau & Jensen, 2014; Steinbrook & Redberg, 2014]). Lastly, the noninterferon based treatments are all oral (pills) administration instead of subcutaneous selfinjections combined with orally administered medications. The medication prescribed and
lengths of treatment are dependent on a thorough assessment of the person’s HCV history (e.g.,
genotype, whether they have cirrhosis, prior HCV treatment, hepatocellular carcinoma [HCC],
HIV co-infection). Patients are considered “cured” when the virus is undetectable in their
blood three months after treatment completion.
Guidelines for Treatment
The Veterans Health Administration (VHA) has established treatment guidelines for
the new HCV medications (Veterans Health Administration, 2015), that require a thorough
pre-treatment assessment to identify mainly the patient’s HCV genotype, viral load, stage of
liver disease (presence or absence of advanced fibrosis/cirrhosis), presence of hepatocellular
carcinoma, HIV co-infection, details of past HCV treatment, and mental health and substance
abuse issues or cognitive limitations that could affect treatment adherence. Furthermore, the
guidelines emphasize that HCV treatment must incorporate strategies to measure and support
adherence to the HCV treatment regimen, given the heightened cost of treatment and Veterans’
expectations for being cured (Slomski, 2014). At the VHA facility where the study took place,
Veterans are required to attend an HCV Education Class (that describes, among other topics,
natural history of HCV, available therapies, candidates for therapy) and an interview with a
health psychologist.
Treatment guidelines for HCV in the US private sector have been somewhat different
from VHA. For individuals receiving HCV treatment in the private sector, insurance
companies have set up barriers for treatment, including limiting access to DAAs only to the
most seriously ill patients as a result of the high cost of these medications. In contrast, most
Veterans receiving HCV care through VHA are eligible for treatment with DAAs. In addition,
VHA receives a 40 percent financial discount on the DAAs from pharmaceutical companies.
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The DAA treatment supports within VHA (e.g., education class, health psychology
assessment) are largely not required in the private sector. Outside the US, pharmaceutical
companies have tiered pricing to make these medications more affordable in developing
countries, where medication pricing is often negotiated with governments (e.g., 10 dollars
instead of up to 1000 dollars per pill; American Association for the Study of Liver Diseases
and the Infectious Diseases Society of America, 2015; Philpott, 2014; Vann & Marcellin,
2015).
HCV Medication Adherence
The World Health Organization (2003) defines treatment adherence as “the extent to
which as person’s behavior – taking medication, following a diet, or making healthy lifestyle
changes – corresponds with agreed-upon recommendations from a health-care provider” (p.
17). More specifically, medication adherence is defined as the patient’s conformance with the
provider’s recommendation with respect to timing, dosage, and frequency of medication-taking
during the prescribed length of time in order to produce a therapeutic result (World Health
Organization, 2003). Unfortunately, approximately 20-30% of all medication prescriptions are
not filled consistently, and nearly 50% of medications prescribed for chronic illnesses are not
taken as prescribed (Brown & Bussell, 2011; Fischer et al., 2011; World Health Organization,
2003). The direct cost of medication non-adherence to the United States health care system is
estimated at $100 billion to $289 billion per year (Osterberg & Blaschke, 2005; World Health
Organization, 2003).
Poor adherence to new HCV medications can similarly be expected to negatively
impact healthcare cost and treatment outcome, given their expense and high adherence
requirements for efficacy. Published research on interferon-based treatment regimens for HCV
indicated that treatment response was directly affected by how closely the medication regimen
was followed (Smith et al., 2007). A person is more likely to achieve a cure with at least 85%
adherence to the medication regimen (DiMatteo, Giordani, Lepper, & Croghan, 2002; Evon et
al., 2013; Lo Re III et al., 2009). Additionally, poor adherence to new DAAs may lead to the
development of resistance to antiviral therapies.
To our knowledge, there has been no published research on factors that facilitate
adherence to the new HCV medication regimens. Published literature on adherence to
interferon-based treatment regimens, however, point to several facilitative factors, including:
the absence of pre-existing psychiatric or substance use disorder, early detection, intervention,
and at least a one month period of total abstinence from substances prior to treatment initiation,
integrating the HCV medical care with mental health and substance abuse services,
implementing necessary support services (e.g., case management, transportation, housing),
establishing rapport in the physician-patient relationship, providing adequate education to
patients on potential effects of the medications, and developing patients’ positive pre-existing
beliefs about the treatment (Edlin et al., 2001; Edlin et al., 2005; Gatti, Jacobson, Gazmararian,
Schmotzer, & Kripalani, 2009; Martin-Santos et al., 2008; Neame & Hammond, 2005;
Sylvestre & Clements, 2007).
The purpose of this study was to identify factors that promote adherence to the new
non-interferon based HCV medications among Veterans. The study originated when the VHA
Chief of the Digestive Diseases Service (third author) contacted the Chief of the Psychology
Service (fourth author) to form a team with her to better understand factors that would support
Veterans’ HCV medication adherence to achieve cure and improve health outcomes. The first
author, who worked as a health psychology fellow in the Digestive Diseases Service, and the
second author, who had qualitative research and integrated primary care/mental health clinical
expertise, joined the team for this project. Currently, all four authors work at VHA in various
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clinical, administrative, and research capacities to support health-related behavior change
among patients who receive medical services in primary care and specialty medical settings.
Methods
This study involved the use of a semi-structured interview and qualitative analysis of
the experiences of Veterans living with HCV who successfully completed their prescribed noninterferon based DAAs. The study was conducted between January and October 2015. No
prior published research had identified factors that facilitate adherence to the new HCV
medication regimens. Thus, the authors took a naïve perspective and used a grounded theory
qualitative approach in order to better understand the Veterans personal experiences taking
these medications. This approach allows for a more open-ended exploration of the participants’
perspectives. Moreover, grounded theory allows for the construction of a theoretical
explanation for the findings that could set the foundation for future research on HCV
medication adherence (Strauss & Corbin, 2000).
Recruitment
Following review and approval by the local Veterans Administration Institutional
Review Board, Liver Clinic medical staff at a local VHA in the Northeast United States
examined the Veterans’ VHA electronic health records and identified 29 HCV-positive
Veterans who had completed a workup to assess candidacy for DAA therapy (including an
HCV Education Class and appointment with a health psychologist), had completed a DAA
treatment regimen for HCV, and were actively engaged in outpatient treatment services within
the Liver Clinic. These Veterans were mailed an opt-out letter, which requested that they call
the research team to indicate if they did not want to participate in the study. If they did not
respond within 10 days, the research team contacted them by telephone to describe the study
and invite them to participate. One opted out. Attempts were made to reach the all remaining
28 Veterans by telephone, including leaving voicemail messages when unavailable. Twelve
Veterans agreed to participate in the study, two Veterans declined participation, and 14 were
not reached. The 12 participants subsequently attended an individual session with research
personnel to complete the verbal informed consent process involving a review of an
information form that outlined the study’s purpose, voluntary nature of participation, and
potential risks/benefits.
Study Participants
Participants in this study were 12 male Veterans. They were mostly Caucasian (92%),
on average about 64 years old, single or divorced (75%), retired or disabled (75%), and from a
variety of military backgrounds during the Vietnam era (75%). Course of prescribed DAA
therapy completed by the participants were as follows: 12-week course = 9 (75%); 16-week
course = 1 (8%); 24-week course = 2 (17%). All participants had undetectable HCV viral loads
at the time of semi-structured interviews. They all had multiple medical and mental health
comorbidities. Two-thirds of the sample had a history of high adherence to prescribed
medications and one-third of the sample had a history of medium to low adherence to
prescribed medications (see Table 1).
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Table 1. Demographic Characteristics.
Variable
Male, n (%)

12 (100%)

Ethnicity, n (%)
Caucasian

11 (92%)

Hispanic

1 (8%)

Age, m (SD)

63.9 (5.5)

Education, n (%)
High School

4 (33%)

Some College

4 (33%)

BA

2 (17%)

Unspecified

2 (17%)

Marital Status, n (%)
Single

4 (33%)

Married

3 (25%)

Divorced

5 (42%)

Household Composition, n
(%)
No other residents
One person

5 (42%)
4 (33%)
3 (25%)

Two people
Residence in Miles from
VHA, m (SD)

34.9 (29.37)

Employment Status, n (%)
Employed

1 (8%)

Unemployed

2 (17%)

Retired

5 (42%)

Disabled

4 (33%)

Branch of Military, n (%)
Army

4 (33%)

Marine Corps

2 (17%)

Navy

4 (33%)
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Air Force

1 (8%)

Marine Corps and Army

1 (8%)

Service Connection, n (%)

6 (50%)

Era of Service, n (%)
Vietnam

9 (75%)

Post-Vietnam

3 (25%)

Combat Exposure, n (%)

5 (42%)

Military Sexual Trauma, n
(%)

0 (0%)

Current Medical Diagnoses,
n (%)
Diabetes
Obesity (BMI>30)
Hypertension
Cirrhosis
Varices
Enchephalopathy
Hepatocellular Carcinoma

4 (33.3%)
3 (25%)
7 (58.3%)
4 (33.3%)
2 (16.7%)
1 (8.3%)
1 (8.3%)
2 (16.7%)

Other Cancers
HIV Infection, n (%)
Detectable HCV Viral Load,
n (%)
Active Mental Health
Diagnosis, n (%)
Depression
PTSD

1 (8.3%)
0 (0%)

5 (42%)
3 (25%)
1 (8.3%)

Bipolar
Current Mental Health
Treatment, n (%)

5 (42%)

Active Substance Use
Disorder, n (%)

1 (8.3%)

Current Substance Abuse
Treatment, n (%)

2 (16.7%)
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History of IV Drug Use, n
(%)
Past 30 Days Outpatient
Clinic Attendance, m (SD)
Medical
Mental Health

7 (58%)

1.9 (1.4)
0.5 (0.7)
0.2 (0.4)

Substance Use
Morisky Adherence
Category, n (%)
High Adherence
Medium Adherence

8 (66.7%)
1 (8.3%)
3 (25%)

Low Adherence
Note. For the Current Medical Disorders category,
the percentages exceed 100% because patients could
have multiple medical comorbidities. For Morisky
prescribed medication adherence scores,
interpretation is as follows: 0 = high adherence; 1-2 =
medium adherence; and 3 or more = low adherence.

The Semi-Structured Interview
All authors developed a semi-structured interview to obtain information about factors
that influenced Veterans’ adherence to the new HCV medications. Questions were open-ended
and designed to elicit perspectives on the experience of living with HCV, being on the new
medications to treat HCV, managing challenges throughout their treatment, and completing a
course of treatment for HCV (see Table 2). The interview was developed successively: (1) the
first author initially drafted questions based on a literature review of issues affecting medication
adherence and in consultation with the Liver Clinic staff; (2) co-authors reviewed and edited
questions to target areas of interest for this study, while minimizing suggestion in questioning;
and (3) the first author conducted mock interviews with Liver Clinic staff to eliminate
redundant items and finalize wording.
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Table 2. Semi-structured Interview.
1) What has it been like for you to have Hepatitis C?
2) Why did you choose to receive the new treatment for your Hepatitis C?
3) What has been your experience being on the new medications for Hepatitis C?
4) Why did you choose to stay on the medication and complete treatment?
5) What were some challenges you experienced along the way while you were on the medication?
a. What, if any, side effects did you experience that you attribute to the Hepatitis C
medication?
b. How did you overcome them?
6) What helped you with your decision to stay on the medication?
7) What does it mean for you to have completed this course of treatment?
8) What do you think we can do to help patients increase their likelihood of completing treatment?
9) What else would be important for me to know in order to get the best understanding of why you
completed Hepatitis C treatment?

Morisky Medication Adherence Questionnaire
This 8-item, self-report measure of patient adherence to prescribed medications
(Morisky, Ang, Krousel-Wood, & Ward, 2008) was administered to participants following
their completion of the semi-structured interview. It has been applied to a broad range of
medications used to treat chronic illnesses and to various cultures (Al-Qazaz et al., 2010; KorbSavoldelli et al., 2012; Morisky, Ang, Krousel-Wood, & Ward, 2008) and has been shown to
be a reliable (α=.83) measure with good concurrent and predictive validity (Bailey et al., 2012;
Morisky, Ang, Krousel-Wood, & Ward, 2008; Reynolds et al., 2012). A total score is
interpreted as follows: 0 = high adherence; 1-2 = medium adherence; and 3 or more = low
adherence.
Semi-Structured Interviewing
After providing consent, Veterans completed the semi-structured interview about their
experiences with taking the new HCV medications. The first author conducted the interviews
using a semi-structured format to guide the line of inquiry (see Table 2). The interviewer
adopted a non-leading style and used open-ended questions to probe for elaboration about
factors influencing the participants’ medication adherence. During the interview process, the
first author took brief manual notes while the participants responded as a means to highlight
words of interest for further inquiry. Information about the participants’ demographic
background, medical issues, and mental health /substance use history was extracted from the
electronic health record following the semi-structured interview. All interviews were audio
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recorded and took about one hour to complete. The first author transcribed all of the recorded
interviews. These interviews were conducted until there was a saturation of data.
Qualitative Data Analysis
All interviews were coded using an adapted coding method outlined by Auerbach and
Silverstein (2003), rooted in grounded theory as described by Strauss and Corbin (2000). The
first and second authors coded and thematically analyzed the interview transcripts. First, each
author independently identified relevant text (i.e., Veterans’ reasons for adherence to the new
HCV medications, factors that facilitated their adherence, and how they successfully managed
barriers that arose during their trial), subgrouped the relevant text into repeating ideas (i.e.,
participants’ use of similar words or sentences to convey the same idea), and coded them within
the transcripts. The authors conducted this open coding line-by-line for all transcripts.
Afterward, the authors compared their coding, resolved discrepancies, and identified
overarching themes from the repeating ideas that describe the Veterans’ subjective experiences.
Next, they categorized themes into theoretical constructs, which function to tie qualitative data
to overarching frameworks through which to understand results. The last author reviewed the
identified repeating ideas, themes, and constructs across four transcripts he randomly selected
from the complete set of 12 and confirmed their presence. Finally, the first author calculated
the percentage of participant interviews in which each theme and repeating idea was present.
Results
Three theoretical constructs, nine themes, and 28 repeating ideas (italicized in text
below) were identified within the transcripts and coded. Table 3 lists the percentage of
participant interviews in which each theme and repeating idea was present.
Table 3. Theoretical Constructs, Themes, and Repeating Ideas.
TC 1: Burden of HCV
T 1: Chronic Illness with Chronic Negative Impact (100%)
RI 1: “I’m Not Healthy” (100%)
RI 2: “It’s Always in the Back of Your Mind” (83.3%)
RI 3: Stigma (50%)
RI 4: Interactions Between Mental Health and Substance Use Disorders (25%)
T 2: Knowledge is Power (100%)
RI 5: Course of HCV and Its Consequences (91.7%)
RI 6: Pros/Cons to New Non-Interferon Versus Interferon-Based Treatments
(75%)
TC 2: Treatment Engagement Process
T 3: Treatment as “No Brainer” (100%)
RI 7: Realistic Hope for Cure (100%)
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RI 8: “I Want to be Healthy” (100%)
RI 9: Improved Quality of Life (83.3%)
T 4: Easy Treatment (91.7%)
RI 10: Simplicity of Regimen (91.7%)
RI 11: Clear End to Treatment (41.7%)
RI 12: Manageability of Side Effects (83.3%)
RI 13: Availability of Medications (83.3%)
RI 14: Aversion to Interferon (83.3%)
T 5: Provider Facilitation of Treatment (83.3%)
RI 15: Clear and Honest Communication (58.3%)
RI 16: Rapport with Providers (50%)
RI 17: Trust for Provider Expertise (83.3%)
T 6: Patient Facilitation of Treatment (100%)
RI 18: Routine for Medication Adherence (75%)
RI 19: Commitment to Behavioral Strategies for Managing Side Effects (91.7%)
RI 20: Self-encouragement (75%)
RI 21: Determination to Complete Treatment (100%)
T 7: Social/Economic Facilitation of Treatment (58.3%)
RI 22: Supports are Key (50%)
RI 23: Cost is Important
TC 3: Positive Outcomes
T 8: “I’m Free” (75%)
RI 24: “I Don’t Have to Worry Anymore” (58.3%)
RI 25: “A New Lease on Life” (58.3%)
T 9: System Variables in New HCV Treatment (83.3%)
RI 26: Satisfaction with the VHA System (50%)
RI 27: “The VA Saved My Life” (58.3%)
RI 28: Areas in Need of Improvement (66.7%)
Note. TC = Theoretical Constructs; T = Themes; RI = Repeating Ideas.
Theoretical Construct 1: Burden of HCV
Theme 1: Chronic Illness with Chronic Negative Impact (100%). All Veterans
discussed their concerns about how HCV progressively impaired their health and would be
fatal without treatment. (“I’m not healthy” [100%]). Veteran’s spoke in detail about how their

194

The Qualitative Report 2018

poor health negatively affected their lives physically, emotionally, and socially (e.g., “I wanted
to get rid of the virus. I want to have a healthy, normal life.”).
Most Veterans noted how “[HCV is] always in the back of your mind” (83.3%). They
emphasized the psychological distress of HCV, even in the absence of physical symptoms (e.g.,
“It’s a burden in itself… you know you’re sick you’re always waiting for the other foot to come
down”).
The stigma of living with HCV emerged as a prevalent theme (50%). Participants
discussed how HCV impaired their social functioning and relationships (e.g., “Stigmatized…
they think that they’re going to catch it if they come in contact with me, like AIDS or
something”).
Some participants (25%) talked about the negative interactions between mental health
and substance use disorders and how having HCV worsened these conditions (e.g., “[HCV]
affected me in all ways…mentally, physically… it was just very stressful…it was wearing on
my whole body”).
Theme 2: Knowledge is Power (100%). Veterans identified knowing about the course
of HCV and its consequences (91.7%) as an important consideration for taking the new noninterferon based HCV medications. They identified the deleterious progression of HCV, its
specific effects on the liver, and what might happen without treatment (e.g., “Knowing it’s
[HCV]…destroying and scarring up my liver…it’s unhealthy, it carries a death sentence”).
Knowledge about the pros/cons of the new non-interferon versus interferon-based
treatments factored into the participants’ decision to adhere to their medication regimens
(75%). Veterans recognized the advantages of the new HCV medications compared to the
drawbacks of the interferon-based treatments, such as length of treatment, flu-like side effects,
and self-injections (e.g., “The liver specialist…advised that ‘if it was me, I wouldn’t take
[interferon], because I believe that there are some medications in the system that would treat
you better’… he said ‘your Hepatitis C ain’t that bad, I would wait until something better comes
in the pipeline’”).
In summary, living with progressive HCV is burdensome to Veterans physical,
psychological, and social well-being. Reflecting Veterans’ specific burdens in juxtaposition
with information about the many benefits of DAAs (e.g., high cure rates, ease of administration,
low side-effect profile) could promote greater HCV medication adherence
Theoretical Construct 2: Treatment Engagement Process
Theme 3: Treatment as “No Brainer” (100%). All participants wanted effective
treatment for their HCV. They spoke about the new medication giving them a realistic hope
for cure (100%). Through their own investigation and in discussions with providers, Veterans
decided the new treatment’s high cure rate made adherence an obvious choice (e.g., “I was
optimistic that I would be cured… that helped a lot”). In addition, all Veterans reported “I
want to be healthy” and saw adherence to the new HCV medications as critical to that goal. A
large portion of Veterans also talked about how treating their HCV could give them an
improved quality of life (83.3%).
Theme 4: Easy Treatment (91.7%). The majority of the Veterans commented on the
relative simplicity of the regimen (91.7%) for the new HCV medications, which promoted their
treatment adherence. Participants liked the pill form and having clear instructions (e.g., “The
protocol is so simple… it’s effortless”).
Some participants liked having a clear end to treatment (41.7%). They discussed how
the clear and specific timeframe for the treatment allowed them to count down their days of
treatment (e.g., “When you’re on this medicine, you have to understand that there’s an end to

Nicole Giordano, Anthony Brinn, Guadalupe Garcia-Tsao, and Steve Martino

195

it eventually…it’s only a temporary treatment for a longer lasting result”), and this bolstered
their adherence.
Several Veterans commented how the manageability of side effects (83.3%) helped
them adhere to the new HCV medications. None of the participants reported any significant
side effects that hampered their ability to complete treatment. Some reported mild physical
side effects, which they managed independently or with the help of providers (e.g., “It’s not
that bad at all, this new medication… side effects were manageable”).
Most Veterans appreciated the availability of medications (83.3%). They discussed
how VHA made the new medications easily available to them, and this availability promoted
their desire to begin and complete the treatment protocol (e.g., “It [new HCV treatment] was
available… they [the VHA] said ‘would you… be interested in trying it?’ so of course I
am…who wants to continue being sick?”).
Many participants commented how their own or others’ past negative treatment
experiences with interferon-based regimens gave them an aversion to interferon (83.3%).
Veterans said these experiences made waiting for the new medications worthwhile and
motivated adherence (e.g., “After the interferon…this [new HCV treatment] was…sweet
sailing… this is like taking aspirin…I kept wondering, is this going to do any good…I don’t
feel anything”).
Theme 5: Provider Facilitation of Treatment (83.3%). Veterans highlighted the
importance of provider facilitation of treatment. Veterans noted that clear and honest
communication (58.3%) helped their medication adherence (e.g., “Conversations…were
straight forward, professional, to the point, answered all my questions, and I felt very
comfortable and that’s what led me to proceed with the medication”). Having rapport with
providers (50%) also mattered to Veterans, particularly in the context of a preexisting positive
patient-provider relationship (e.g., “I had a pretty good relationship with my doctor…I had
been seeing him a little while…we had a little rapport”).
Veterans talked about having trust for provider expertise (83.3%). They respected their
providers as knowledgeable medical professionals and followed their HCV treatment advice
(e.g., “I believe that it’s important for me to work with my providers to ensure the best possible
results in maintaining a good state of health. I do my part; I can’t do the medical part with
limited knowledge and limited access to whatever’s necessary, so I trust the system”).
Theme 6: Patient Facilitation of Treatment (100%). Patient’s also engaged in
behaviors that supported their medication adherence. Three-fourths of the sample reported that
establishing a routine for medication adherence was helpful. Participants described integrating
the HCV medication regimen into their preexisting daily routines (e.g., “I arranged it so I take
a thyroid medication first thing in the morning …every day and then I would take the
medication…at the same time”).
Moreover, most Veterans made a commitment to behavioral strategies for managing
side effects (91.7%). Veterans spoke about how they attempted to cope with medication side
effects by trying strategies recommended by providers or other patients (e.g., “I’m a very
impatient person to begin with, but that…multiplied…when I was on that stuff [new HCV
medication]. I really had to count to 10 a lot…I’ve got calendars…I got a pad on my desk and
I write down everything.”).
Veterans typically used self-encouragement to promote adherence (75%) (e.g., “I can
do this.” or “It was only the last two weeks of the program and I kept saying to myself, you
only got two more weeks on it, just do it… I had a countdown… all of a sudden… I was right
at the end of it”). Veterans reported that this self-encouragement gave them determination to
complete treatment using all available resources during treatment (e.g., “I was determined to
do it.”).

196

The Qualitative Report 2018

Theme 7: Social/Economic Facilitation of Treatment (58.3%). Veterans reported
that supports are key (58.3%) to success. Veterans talked about how outside support from
family and friends helped them to begin the regimen, cope, adhere, and complete the regimen
(e.g., “[My wife’s] always been there to push…my wife handles most of the medication.”). In
addition, some Veterans spoke about how cost is important (25%) and that knowledge of how
costly the new medications are made them more motivated for adherence (e.g., “I think the VA
hospital has been more than kind in asking me to do this…I know how expensive it is and I
appreciate it and I just wanted to go along with their program.”).
These seven themes underscore factors that could better engage Veterans in their HCV
treatment. Veterans’ adherence to DAAs could be maximized by emphasizing their realistic
hope for cure and expectations for an improved quality of life given the effectiveness of these
medications and their simple, clearly delineated regimens. Moreover, teaching Veterans
strategies to improve medication adherence, facilitating collaborative patient-provider working
relationships that foster trust, and leveraging extant social supports could further support
Veterans’ efforts to take their HCV medication regimens as prescribed over the full course of
treatment.
Theoretical Construct 3: Positive Outcomes
Theme 8: “I’m Free” (75%). Veterans said “[they] don’t have to worry anymore”
(58.3%) about being HCV positive and reported a decrease in psychological distress and
anxiety following the completion of the medication trial (e.g., “Knowing that…Hepatitis C is
at a level where it’s not traceable, it can give me peace of mind…put my mind at ease, one less
thing to worry about.”).
Many Veterans felt they had “a new lease on life” (58.3%) following treatment
completion. They noted having improved relationships and social functioning and discovering
new purpose and value in life (e.g., “I’ve been given a new lease on life… it helped me to be
more mindful of how I attended to my day-to-day… with nutrition, exercise… supports, a
refinement of my values and a sense of… purpose”).
Theme 9: System Variables in New HCV Treatment (83.3%). Participants
identified how VHA had successfully established a treatment-accessible system for Veterans
to receive the new HCV medication. Half of participants reported relative satisfaction with the
VHA system. Veterans talked about how the structure implemented in the Liver Clinic helped
them adhere to treatment (e.g., “I was at the hospital every two weeks and that was important
because… I kept up with my medication… they… guide you… sometimes you’re on a
medicine that can have an effect on your mind, you can tend to stop taking the medicine or you
don’t take it properly and that can affect the outcome”).
More than half of the Veterans felt “the VA saved my life” (58.3%). Veterans
appreciated that the VHA provided Veteran’s with the new HCV medication (e.g., “The VA
basically saved my life.”). Nonetheless, Veterans noted areas in need of improvement to
maximize medication adherence within the VHA system (66.7%) (e.g., “More contact from a
doctor or from a professional type of person through the course of the medication… I met with
the doctor every two weeks, but that was quick.”).
Successful completion of the HCV treatment regimen resulted in decreased
psychological distress and ability to re-engage in productive life activities and social
relationships. Bringing emphasis to these positive outcomes and experiences could promote
medication adherence. More contact with treatment team members could further improve
DAA adherence.

Nicole Giordano, Anthony Brinn, Guadalupe Garcia-Tsao, and Steve Martino

197

Discussion
Three qualitatively derived theoretical constructs involving the experiences of
Veterans’ who successfully completed the new HCV medication trials elucidated factors that
likely affected their medication adherence: burden of HCV, treatment engagement process, and
positive outcomes. Veterans described burdensome psychological distress, anxiety, and worry
about having HCV and knowing about the progressively negative and ultimately fatal health
consequences of the disease. Learning about the more efficacious and tolerable non-interferon
based medications, relative to prior medication options, gave Veterans hope they could lift
these burdens and solidified their commitment to medication adherence.
Veterans highlighted the importance of the treatment engagement process. To them, it
was a “no brainer” when providers presented to them the high efficacy rates, treatment
simplicity, decreased length of treatment with a clear end point, and manageable side effects
compared to interferon-based regimens. Veterans looked forward to the ability to transform
from “unhealthy” individuals to “healthy” people who had a chance to improve the quality of
their lives.
Provider, patient, and social/economic factors also facilitated medication adherence.
Conditions facilitating adherence included: (1) having a strong working relationship with one’s
provider based on trust, open communication, rapport, and respect; (2) harnessing patientdriven strategies to promote adherence, such as incorporating the new medications into
preexisting routines, using strategies to cope with medication side effects, and engaging
regularly in positive self-talk and encouragement; (3) enlisting support from family and friends;
and (4) heightening awareness about the cost of treatment and the opportunity provided to
Veterans to receive the new HCV medications. These conditions facilitating adherence support
the previously published literature regarding the importance of implementing necessary
support services (e.g., case management, transportation, housing), establishing rapport in the
physician-patient relationship, providing adequate education to patients on potential effects of
the medications, and developing patients’ positive pre-existing beliefs about the treatment
(Edlin et al., 2001; Edlin et al., 2005; Gatti, Jacobson, Gazmararian, Schmotzer, & Kripalani,
2009; Martin-Santos et al., 2008; Neame & Hammond, 2005; Sylvestre & Clements, 2007).
Upon treatment completion, Veterans report feeling “free,” having a new chance at
developing healthy relationships, an improved sense of purpose, and a desire to better their
lives more broadly (e.g., eating healthier, exercising, being abstinent from substances of abuse,
getting additional support for mental health or other medical issues). Most Veterans reported
satisfaction with the local VHA system’s structure and process for providing the new HCV
treatment, and they expressed appreciation and gratitude to the VHA for giving them access to
it. In short, they felt they were given “a new lease on life” and wanted VHA healthcare
providers to enhance services by providing Veterans prescribed the new HCV medications
more professional medical contact throughout the course of treatment.
Clinical Implications
This study suggests that older, medically compromised HCV-positive Veterans view
adherence to the new non-interferon DAAs as a fortuitous opportunity to improve their health
and quality of life. Veterans, their providers, and VHA policy makers are invested in achieving
these life-changing positive outcomes (Veterans Health Administration, 2015). To maximize
adherence to these medications, providers should consider the individual medical,
psychological, and social burdens stemming from having HCV, educate Veterans about the
fatal progression of the disease if left untreated, and introduce information about the
acceptability, feasibility, and efficacy of the new medications as a likely pathway to cure. In
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addition, given that many HCV-positive Veterans may hold negative views of HCV medication
intervention based on their experiences in previous interferon-based treatment trials,
distinguishing the new class of HCV medications from interferon-based treatment is
particularly important. Talking with Veterans in this manner about benefits of the new vs.
older HCV medication options is consistent with motivational enhancement interventions that
help patients explore and resolve their ambivalence toward behavior change (Magill et al.,
2014). Providers should also help patients develop specific medication adherence plans that
identify when patients might take their medications, how they will manage side effects, and
how they will encourage themselves to continuously adhere to their regimens. Establishing
rapport, building trust, and being clear and honest with patients about their treatment plan,
including addressing comorbid mental health and substance use issues, could further maximize
patient medication adherence. Moreover, underscoring the positive outcomes reported by other
patients who have completed HCV medication trials, perhaps through testimonials, might lend
additional confidence and hope to patients who want medical relief and physical and mental
rejuvenation from HCV. These various factors for promoting adherence underscore the
importance of tailoring one’s interventions to the Veteran. Depending on the Veterans and
their presenting concerns, certain areas might be more of a focus for their purposes of
maximizing their medication adherence.
Veterans in this study expressed gratitude for having access to the new and expensive
DAAs and recommended even more contact with their providers during the course of
treatment. Specialty medical services may be limited in the amount of additional in-person
contact that can be provided (Ford et al., 2012). However, the VHA has many other clinical
interventions that could support new HCV medication adherence, such as nurse case managers
(Piette, Weinberger, Kraemer, & McPhee, 2001), health psychology consultations (Zeiss &
Karlin, 2008), and telehealth interventions such as in-home messaging devices to monitor and
prompt adherence (Darkins et al., 2008). In addition, offering Veterans support groups
(Perlman, Cohen, Altiere, Brennan, Brown, & Mainka, 2010), shared medical visits (Watts et
al., 2009), and increased coordinated contact with other professionals involved in treatment
(e.g., mental health or substance use provider) could further promote Veterans’ adherence to
the new HCV medications.
Current VHA Treatment for HCV
The VHA, being the largest HCV care provider in the United States, has seen a rapid
growth in the number of Veterans seeking treatment with the new DAAs (US Department of
Veterans Affairs, 2015a; US Department of Veterans Affairs, 2015b; Veterans Health
Administration, 2015). Initially, the VHA reported that cost would not be a factor in
prescribing the new medications (Ross, 2013), and all Veterans that wanted to be treated were
to be treated (Veterans Health Administration, 2015). With this recommendation, 17% of the
VHA’s total pharmacy budget for fiscal year 2015 was allocated to the new HCV medications,
totaling $696 million (Flynn, 2015). Nearing the end of the fiscal year 2015, the VHA faced a
budget deficit of more than $2.5 billion, largely attributable to the provision of these new
medications (Daly, 2015; Oppel, 2015). In response to this deficit, VHA began using the
Choice Program to refer Veterans interested in HCV treatment to community, non-VHA
providers (Daly, 2015). Along with this outsourcing of treatment, only those Veterans with
advanced liver disease are considered top priority for treatment (US Department of Veterans
Affairs, 2015a; US Department of Veterans Affairs, 2015b; Wagner, 2015). Given that this
study was conducted with Veterans who received HCV treatment within the VHA, it remains
unclear what effect the Choice Program will have on Veterans’ experiences being treated for
HCV and their rates of adherence to the new HCV medications.
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Study Limitations and Implications for Future Research
This study’s generalizability is limited by its small sample size, focus on older Veterans,
and implementation during the initial release of the new HCV medications. Future studies
should assess how younger and less medically ill Veterans with HCV view access and
adherence to the new HCV medications. Factors affecting their adherence may differ from this
study’s sample in that the burdens of HCV may not have accumulated to the same degree.
Likewise, with the advent of the Choice Program at the VHA and evolving healthcare insurance
policies in the United States, the HCV treatment experiences of patients may change, which
could influence medication adherence in different ways. In addition, qualitatively examining
factors that affect patients who did not complete their new HCV medication treatment trials is
needed to identify new strategies to keep patients at risk for dropout in treatment. Participants
in this study had completed varying lengths of HCV treatment, including 12-, 16-, and 24weeks. Future studies should consider how the length of treatment impacts adherence. Finally,
following a cohort of Veterans over a longer course of time post medication trial, identifying
the accrued benefits, and conducting cost-benefit analyses could provide helpful information
to Veterans and inform both healthcare policy and funding decisions as negotiated pricing and
HCV treatment services continue to evolve in VHA and non-VHA care settings (American
Association for the Study of Liver Diseases and the Infectious Diseases Society of America,
2015).
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